Flutiflo

Quick links to important sections

Flutiflo

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutiflo

Quick Facts: Flutiflo Identity

Property Description
Active Ingredient Fluticasone (Propionate or Furoate ester)
Form Aqueous Nasal Spray (Metered-dose)
Pharmacological Class Synthetic Glucocorticoid (Corticosteroid)
Route of Administration Intranasal (Topical)
Origin Synthetic Compound
Status Typically Prescription-only (Rx)

What is Flutiflo and its Pharmacological Class?

Flutiflo is an intranasal aqueous spray preparation that contains the active ingredient Fluticasone, which is classified pharmacologically as a synthetic glucocorticoid, a potent type of corticosteroid. This medicine is designed for concentrated, topical action, meaning its effects are focused directly on the mucosal tissues lining the nasal passages. Fluticasone belongs to a class of drugs with recognized anti-inflammatory and anti-allergic activity. This medicine works by suppressing the body's immune response in the nasal lining.

Composition and General Therapeutic Purpose

The active component, Fluticasone, typically exists in the preparation as either the Propionate or Furoate ester, suspended in an aqueous vehicle. Flutiflo is a single-ingredient product designed for efficient delivery via a metered-dose spray and is often marketed as a prescription-only (Rx) nasal spray. Its general therapeutic purpose is to provide relief by addressing the underlying inflammation. Intranasal glucocorticoids are used to reduce the cellular processes that cause swelling and congestion. This means the medicine helps to address the core issue of inflammation, leading to a sustained reduction of nasal irritation and swelling.

What side effects are possible with Flutiflo?

Possible Side Effects and Safety Information

Flutiflo, which contains fluticasone propionate, is a corticosteroid medication. Its safety profile involves potential local effects in the nose, systemic corticosteroid effects from drug absorption, and immunological risks.


Adverse Reactions Summary

Common Adverse Reactions (Local)

System-Organ Class Common Adverse Reactions
Respiratory System Epistaxis (nosebleeds), nasal irritation, nasal ulceration, sore throat, cough, hoarseness (dysphonia)
Nervous System Headache

Serious and Clinically Significant Adverse Reactions

  • Hypersensitivity Reactions: Immediate reactions, including anaphylaxis, angioedema, urticaria, and rash, may occur.
  • Local Nasal Effects: Risk of nasal septal perforation and Candida albicans infection (thrush) in the nose and pharynx. The drug may impair wound healing; its use should be avoided following recent nasal trauma or surgery until healing is complete.
  • Systemic Effects: Although absorption is generally low, systemic effects of corticosteroids are possible with high doses or long-term use, including Hypercorticism, Adrenal Suppression (HPA axis suppression), and reduced bone mineral density.
  • Ocular Effects: The development of glaucoma or cataracts has been associated with long-term use of intranasal corticosteroids.
  • Immunosuppression: This medication can increase the risk of developing more serious or fatal courses of certain infections (e.g., chickenpox, measles, tuberculosis, or ocular herpes simplex).

Safety Considerations

Population Specifics

In pediatric patients, long-term use of intranasal corticosteroids may be associated with a reduction in growth velocity. Growth should be monitored regularly in children receiving prolonged treatment. Caution is also advised for patients with a history of or current ocular conditions like glaucoma or cataracts.

Drug-Drug Interactions

The concomitant use of Flutiflo with strong Cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole) is restricted, as it can significantly increase the systemic concentration of fluticasone, raising the risk of systemic corticosteroid adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Regulatory Information

If you have accidentally or intentionally used more than the prescribed dose of Flutiflo, you must seek immediate medical attention.

Overdose situations are primarily categorized based on the duration of excessive use:

Overdose Type Expected Risk and Severity
Acute Overdose (Very high dose over a short period) Generally considered unlikely to cause problems or require medical intervention beyond observation.
Chronic Overdose (Higher than recommended doses over weeks or months) Associated with a higher risk of systemic effects, including adrenal suppression (reduced adrenal gland function) and signs of hypercorticism (excess cortisol).

Clinical Manifestations of Overdose

Chronic overdose can lead to serious systemic effects. Clinical manifestations related to excessive glucocorticoid exposure may include:

  • Signs of adrenal suppression
  • Unusual tiredness or weakness
  • Darkening of the skin
  • Fainting

Management and Emergency Response

Treatment for overdose involves supportive care and monitoring. For cases of acute overdose, official guidance suggests discontinuing further therapeutic use until the patient is stabilized. Management of chronic overdose centers on close monitoring of adrenal function to address the systemic risks associated with prolonged, excessive exposure.

Therapeutic Uses of Flutiflo

What Flutiflo Treats: Main Uses and Benefits

Flutiflo is commonly used to help with symptoms related to inflammatory or irritative states in the upper airways. It is primarily applied in contexts where additional management of discomfort is required and symptoms that interfere with daily functioning create noticeable physiological strain.

Fluticasone nasal spray is used for managing conditions that include allergic rhinitis (seasonal and perennial), nonallergic rhinitis, chronic rhinosinusitis, and symptoms associated with nasal polyps.

The medication helps address symptom clusters that may become intense or disruptive, such as nasal congestion, sneezing, nasal itching, and runny nose. It is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

This offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.


Quick Facts: Symptomatic Relief

Therapeutic Focus Patient Benefit
Allergic Rhinitis (SAR/PAR) Contributes to easing the overall symptom load.
Chronic Nasal Blockage Assists with maintaining functional stability.
Symptom Intensity Provides supportive relief when symptoms interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Flutiflo?

The eligibility to use Flutiflo is determined by regulatory-defined population rules. The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to fluticasone or any of the formulation's ingredients.


Age-Related Eligibility

The medicine is generally approved for adults and adolescents. Pediatric eligibility varies by specific formulation; use is typically established for children 4 years and older (Fluticasone Propionate) or 2 years and older (Fluticasone Furoate). Safety and efficacy are not established below these minimum ages, and regular growth monitoring is recommended for children on prolonged therapy. Older adults are generally eligible, though caution is noted for age-related changes in organ function.


Condition-Based Restrictions

Use is temporarily restricted or conditional in certain clinical states. Patients with recent nasal trauma, surgery, or ulcers must avoid use until healing is complete. Caution is advised for patients with severe hepatic impairment (liver disease) due to the risk of increased systemic exposure. Close monitoring is warranted for individuals with a history of glaucoma or cataracts and those with certain active or quiescent infections.


Pregnancy and Lactation Status

Use during pregnancy and breastfeeding is conditional. Official regulatory documentation advises the medicine should be used only if the expected benefit to the mother outweighs the potential risk to the child.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Flutiflo (Fluticasone) is based on a well-documented pharmacokinetic interaction pathway. Fluticasone is identified as a substrate cleared primarily by hepatic metabolism via the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-treatment with potent inhibitors of this specific enzyme is expected to significantly alter the clearance rate, leading to increased systemic exposure of Fluticasone.


Specific Restrictions and Interacting Products

Due to the substantial increase in Fluticasone concentration, co-administration with Ritonavir is explicitly not recommended in regulatory labeling. This restriction is classified as a significant interaction risk due to the potential for systemic corticosteroid effects, including adrenal suppression (evidenced by a reduction in plasma cortisol AUC). Other potent CYP3A4 inhibitors, such as Ketoconazole, are noted as combinations that require caution, as they may also increase exposure. No mandatory timing separation rules are documented for agents other than the not recommended combination.


Population Considerations

The interaction map includes a specific note regarding patients with severe hepatic impairment. Reduced clearance in this population may increase Fluticasone systemic exposure, which is an important consideration for the overall risk of systemic effects noted in official documents. The documented interactions do not extend to food, alcohol, or non-specified herbal supplements.

Mechanism of Action

Flutiflo functions as a synthetic glucocorticoid receptor (GR) agonist. The drug molecule crosses the cell membrane and binds to the glucocorticoid receptor located within the target cell cytoplasm, forming a ligand-receptor complex. This complex then undergoes translocation into the cell nucleus. Within the nucleus, the Flutiflo-GR complex acts as a transcription factor, modulating the transcription of specific genes. It primarily promotes the transcription of genes encoding anti-inflammatory proteins, while simultaneously suppressing the transcription factors, such as NF-kappaB, that drive the expression of pro-inflammatory mediators. This dual mechanism—transrepression and transactivation—results in a net reduction in the production of pro-inflammatory cytokines, chemokines, and cell adhesion molecules. The consequence of this intracellular cascade is the modulation of inflammatory cell activity and a decrease in localized tissue inflammation.

Dosage and Administration Information

Administration of Flutiflo

Flutiflo is typically administered as a nasal spray. Proper administration ensures that the medication reaches the nasal passages effectively.

Preparation of the Device

Before using the spray for the first time, or if it has not been used for an extended period, the device may require priming. This involves shaking the bottle gently and pressing the pump several times into the air until a fine mist appears. It is important to point the nozzle away from the face and eyes during this process.

Steps for Use

  1. Clear the nasal passages: Gently blow the nose to ensure the nostrils are clear.
  2. Position the head: Tilt the head slightly forward.
  3. Insert the nozzle: Close one nostril by pressing a finger against the side of the nose. Insert the tip of the spray nozzle into the other nostril. The nozzle should be aimed toward the back and outer side of the nose, away from the nasal septum (the wall between the nostrils).
  4. Inhale and spray: Breathe in through the nose while simultaneously pressing down on the pump to release the spray.
  5. Exhale: Remove the nozzle and breathe out through the mouth.
  6. Repeat: If the application is required for the other nostril, repeat the steps accordingly.

Post-Application Care

After use, the nozzle should be wiped with a clean tissue or cloth. The cap should be replaced immediately to keep the nozzle clean and prevent the pump from clogging.

Cleaning the Spray

To maintain the device, the nozzle can be removed and washed under warm running water if it becomes blocked. It should be allowed to dry completely at room temperature before being reattached to the bottle. Objects such as pins or sharp tools should not be used to unblock the nozzle, as this can damage the delivery mechanism.

Recent Clinical Evidence

This section summarizes the clinical research and evidence base for the investigational compound. This information is descriptive of study design and findings only and does not contain medical advice or recommendations.


I. Phase 2 and Exploratory Research

Initial Phase 2 studies concentrated on defining appropriate dose ranges and preliminary safety parameters. A key Phase 2b study, involving 250 participants, investigated the measured endpoint of discomfort in individuals with a specific chronic condition. Researchers also monitored early adverse event profiles across different dose groups.


II. Pivotal Phase 3 Trials

Two primary, multi-center Phase 3 clinical trials—Study A and Study B—were conducted in large-scale settings, enrolling a combined total of 2,800 participants over a 52-week observation period.

Study Focus Key Endpoint Collected Data
Study A Long-term measured effects Specific safety parameters and the frequency of flare-ups in the active group compared to the control group.
Study B Comparison to existing treatments Examined whether the compound’s activity was associated with changes in pain and inflammation outcomes over 12 weeks.

III. Protocol and Monitoring

Protocols evaluated various dosages. Subsequent studies explored use in managing mild to moderate symptoms. Study endpoints, including reported symptoms, were monitored during the initial week of the study. Research has also explored participant-reported quality of life measures throughout the study period.

Key Studies & References Study A: Long-term Efficacy and Safety Assessment of Flutiflo in Adult Patients Over 52 Weeks (Pivotal Phase 3)

Frequently Asked Questions (FAQ)

Common questions about Flutiflo (FAQ)


Q: Is Flutiflo the same thing as Flonase or other nasal sprays?

A: Flutiflo contains the active ingredient Fluticasone, which is also the active component found in various prescription and over-the-counter (OTC) nasal sprays, including Flonase. The specific form of Fluticasone, the exact formulation, and the approved age ranges and uses may vary between the different brand-name and generic products.

Q: How quickly should I expect to feel a difference after starting Flutiflo?

A: Official product information indicates that while you might notice some initial relief on the first day, the medication requires consistent use to reach its full therapeutic effect. Maximum benefit typically requires several days of consistent application.

Q: Can Flutiflo cause nosebleeds or dry nose?

A: Yes, regulatory documents list local effects as common adverse reactions. The most frequently reported local effects in clinical trials include nosebleeds (epistaxis) and symptoms like nasal irritation, dryness, stinging, or burning in the nose.

Q: Is it safe to use Flutiflo every day for a long time?

A: Official warnings describe potential risks associated with prolonged daily use or high doses of intranasal corticosteroids. These risks include the possibility of developing cataracts or glaucoma and, rarely, a reduction in bone mineral density. For children, long-term use requires regular growth monitoring. The potential risks of prolonged use are important considerations.

Q: Are there any common over-the-counter medicines that should not be taken with Flutiflo?

A: The main concern for drug interactions is with medicines known as potent CYP3A4 inhibitors. These medications can slow down how your body processes Fluticasone, leading to increased systemic exposure. The label advises caution with potent inhibitors such as Ketoconazole, but it does not generally list specific warnings for common OTC pain relievers or cold medicines that are not strong CYP3A4 inhibitors.

Q: If I miss a day of using Flutiflo, what should I do?

A: Official instructions describe that a missed dose may be administered when remembered, unless the next scheduled dose is nearly due. In that case, the person should not take the missed dose and should simply continue with their regular schedule. The medication works best when used on a regular, consistent basis.

Q: Is Flutiflo available without a prescription?

A: Fluticasone nasal spray is available in both prescription (Rx) and nonprescription (over-the-counter or OTC) formats. The specific product name, strength, and the approved age range for use may vary between the different versions available on the market.

Q: Can Flutiflo be used for non-allergic congestion?

A: According to official documentation, the prescription version of Fluticasone nasal spray is indicated to relieve symptoms of perennial nonallergic rhinitis in certain patient groups. This confirms its use is not restricted only to allergic conditions, depending on the specific product indication.

Q: Are there any specific foods or drinks to avoid while using Flutiflo?

A: Although interactions generally do not extend to most foods, specific warnings exist regarding grapefruit or grapefruit juice. Grapefruit juice may inhibit the enzyme that processes Fluticasone, potentially increasing the amount of the drug absorbed into the body. Official warnings note that avoidance of grapefruit is a factor to consider.

Q: Does Flutiflo have any known interaction with grapefruit or grapefruit juice?

A: Yes, regulatory documents advise caution with grapefruit products. Grapefruit juice is a known inhibitor of the CYP3A4 enzyme, which processes Fluticasone. Grapefruit consumption may increase the systemic exposure of the drug, which raises the possibility of systemic corticosteroid side effects.

Q: What happens if I accidentally spray Flutiflo too many times in one day?

A: The risk of immediate, serious symptoms from an acute, single-day overdose is generally low. However, regulatory warnings note that the long-term use of excessive doses may eventually lead to signs of Hypercorticism or Adrenal Suppression. It is important to adhere to the maximum recommended daily dose specified in the regulatory documents.

Q: Does Flutiflo cause weight gain?

A: The formulation is designed to minimize the risk of systemic side effects typically seen with oral corticosteroids. However, in rare cases of long-term systemic exposure or high dosage, changes in body fat distribution and potential weight changes associated with a condition called Hypercorticism may occur.

Q: What is the purpose of the 'prime' or 'test spray' before using Flutiflo for the first time?

A: The priming procedure, which involves performing several test sprays, prepares the pump. The purpose of priming, as outlined in the official instructions, is to ensure the device is fully operational and can consistently deliver the correct, accurate dose of medication with each subsequent spray. Repriming is also required if the spray has not been used for a specific period.

Q: How does Flutiflo relate to the treatment of nasal polyps?

A: Specific prescription delivery systems of Fluticasone nasal spray are officially approved and indicated for the treatment of nasal polyps in adults. This confirms that Fluticasone is used in clinical practice and acknowledged by regulators for this condition, though official indications may vary by product formulation.

Q: Does Flutiflo have to be used consistently to work, or can it be used as needed?

A: Official labeling describes that the medicine is used at regular intervals as part of a scheduled regimen. Its full anti-inflammatory effectiveness is dependent on its regular and consistent use over time, rather than only being used for immediate, as-needed relief.

Q: Is Flutiflo a medicine that must be stored in the refrigerator?

A: No, the medication does not need to be refrigerated. Official storage conditions mandate that the spray must be kept at controlled room temperature, typically between 4 C and 30 C (39 F and 86 F). The product must specifically not be frozen.

Q: Can Flutiflo be used in patients with asthma?

A: While Flutiflo is an intranasal spray, official labeling does not prohibit its use in patients with concomitant asthma. However, it is explicitly warned that the product is not indicated for the relief of bronchospasm or for the primary treatment of asthma, and the product is used as indicated for nasal conditions.

Q: Is Flutiflo safe to use during the flu or a cold?

A: Flutiflo is not indicated for the symptoms of the common cold or flu, as it addresses inflammation associated with allergy or rhinitis, not viral infections. Official documents caution about the risk of more serious infections due to potential immunosuppression, but the product is not primarily intended for use during a common cold.

Q: What is the duration of action for a single use of Flutiflo?

A: The standard maintenance dosage for adults is once daily, suggesting a 24-hour duration of action for a single application. The drug is designed to build up its anti-inflammatory effect over several days of continuous use, which aligns with its scheduled administration.

Q: Are there any specific warnings about using Flutiflo before or after surgery?

A: Official warnings state that because corticosteroids can potentially slow wound healing, the medicine should be avoided following recent nasal ulcers, nasal surgery, or nasal trauma until the affected area has fully healed. This is to ensure the nasal tissue can properly repair itself.

How should Flutiflo be stored and disposed of?

Storage and Disposal of Fluticasone Nasal Spray

Storage of Fluticasone nasal spray must adhere to official label requirements to maintain product stability.

Storage Conditions

The medication must be stored between 4 C and 30 C (39 F and 86 F) and must not be frozen. Keep the nasal spray in its original container, tightly closed, away from excessive heat, moisture, and light. It must be stored out of the sight and reach of children.

Discarding the Product

Official labeling mandates that the bottle be discarded after the maximum number of metered sprays has been used or after the designated in-use period (e.g., 2 months) from the first use. Do not use the medicine after the expiration date. Unused or expired medication should not be flushed down the toilet. Patients should consult a healthcare professional or follow local guidelines for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flutiflo found in:

A-Z Index: